Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

[Secondary and tertiary prevention of atherosclerotic vessel disease].

Husmann F.

Z Arztl Fortbild Qualitatssich. 2000 Apr;94(3):195-8. German.

PMID:
10802893
[PubMed - indexed for MEDLINE]
3.

Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.

Langer RD, Landgren BM, Rymer J, Helmond FA; OPAL Investigators.

Am J Obstet Gynecol. 2006 Nov;195(5):1320-7. Epub 2006 Jul 26.

PMID:
16875644
[PubMed - indexed for MEDLINE]
4.

Beyond the null hypothesis--do the HERS results disprove the estrogen/coronary heart disease hypothesis?

Blumenthal RS, Zacur HA, Reis SE, Post WS.

Am J Cardiol. 2000 Apr 15;85(8):1015-7. No abstract available.

PMID:
10760346
[PubMed - indexed for MEDLINE]
5.

Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.

Chang TC, Lien YR, Chen M, Cheng SP, Chen RJ, Chow SN.

Acta Obstet Gynecol Scand. 2004 Jul;83(7):661-6.

PMID:
15225192
[PubMed - indexed for MEDLINE]
6.

Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial.

Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E; Heart and Estrogen/progestin Replacement Study.

Ann Intern Med. 2003 Jan 7;138(1):1-9.

PMID:
12513038
[PubMed - indexed for MEDLINE]
7.

The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort.

Herrington DM, Reboussin DM, Klein KP, Sharp PC, Shumaker SA, Snyder TE, Geisinger KR.

Control Clin Trials. 2000 Jun;21(3):257-85. Erratum in: Control Clin Trials 2000 Aug;21(4):414.

PMID:
10822123
[PubMed - indexed for MEDLINE]
8.

Hormone replacement therapy should be administered as secondary prevention of coronary artery disease.

Spencer AP.

Pharmacotherapy. 2000 Sep;20(9):1028-33. Review.

PMID:
10999493
[PubMed - indexed for MEDLINE]
9.

Predictors of heart failure among women with coronary disease.

Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, Shlipak MG.

Circulation. 2004 Sep 14;110(11):1424-30. Epub 2004 Sep 7.

PMID:
15353499
[PubMed - indexed for MEDLINE]
Free Article
10.

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.

Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR; Women's Health Initiative Investigators.

Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73.

PMID:
15863546
[PubMed - indexed for MEDLINE]
11.
12.

Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study.

Simon JA, Hunninghake DB, Agarwal SK, Lin F, Cauley JA, Ireland CC, Pickar JH.

Ann Intern Med. 2001 Oct 2;135(7):493-501.

PMID:
11578152
[PubMed - indexed for MEDLINE]
13.

Anticipating HERS: questions from the Heart and Estrogen/Progestin Replacement Study.

Barrett-Connor E, Stuenkel CA.

J Womens Health. 1998 May;7(4):395-7. No abstract available.

PMID:
9611695
[PubMed - indexed for MEDLINE]
14.

Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.

Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, Allison M, Bonds DE, Masaki K, Caralis P, Kotchen JM; Women's Health Initiative Investigators.

Circulation. 2004 Feb 10;109(5):620-6.

PMID:
14769684
[PubMed - indexed for MEDLINE]
Free Article
15.

The time has come to stop letting the HERS tale wag the dogma.

Mendelsohn ME, Karas RH.

Circulation. 2001 Nov 6;104(19):2256-9. No abstract available.

PMID:
11696459
[PubMed - indexed for MEDLINE]
Free Article
16.

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ.

Ann Intern Med. 2000 Dec 19;133(12):933-41.

PMID:
11119394
[PubMed - indexed for MEDLINE]
17.

Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.

Limpaphayom KK, Darmasetiawan MS, Hussain RI, Burriss SW, Holinka CF, Ausmanas MK.

Climacteric. 2006 Jun;9(3):204-14.

PMID:
16766434
[PubMed - indexed for MEDLINE]
18.

Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study.

Hsia J, Simon JA, Lin F, Applegate WB, Vogt MT, Hunninghake D, Carr M.

Circulation. 2000 Oct 31;102(18):2228-32.

PMID:
11056097
[PubMed - indexed for MEDLINE]
Free Article
19.

[Use of estrogen-progestins in secondary prevention].

Modena MG, Origliani G, Rossi R.

Ital Heart J Suppl. 2000 Mar;1(3):435-6. Italian. No abstract available.

PMID:
10815281
[PubMed - indexed for MEDLINE]
20.

Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.

Howard BV, Hsia J, Ouyang P, Van Voorhees L, Lindsay J, Silverman A, Alderman EL, Tripputi M, Waters DD.

Circulation. 2004 Jul 13;110(2):201-6. Epub 2004 Jun 28.

PMID:
15226212
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk